Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Rescinds Zofran ODT ANDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

A prior court decision that Par's ondansetron infringes an unexpired GSK patent prompts FDA to revoke approval.

You may also be interested in...



Hana Biosciences Prepares To Submit First Ondansetron Oral Spray

Pivotal trials confirm Zensana spray is bioequivalent to Zofran tablets for chemotherapy induced nausea and vomiting.

Hana Biosciences Prepares To Submit First Ondansetron Oral Spray

Pivotal trials confirm Zensana spray is bioequivalent to Zofran tablets for chemotherapy induced nausea and vomiting.

Par Acquisition Of Kali Will Help Boost Product Offerings 50% In Two Years

Par will pay $135 mil. for the New Jersey-based generic drug firm. The combined company will have 37 pending ANDAs, including first-to-file application for generic version of J&J's Ultracet.

Related Content

Topics

UsernamePublicRestriction

Register

PS061322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel